RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 4
Clinical trials for RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 4 explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 4 trials appear
Sign up with your email to follow new studies for RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 4, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Fat stem cells injected into brain during surgery to fight returning tumors
Disease control Recruiting nowThis early-stage trial tests whether stem cells taken from body fat and placed directly into the brain during surgery can help treat glioblastoma that has come back. About 20 adults with recurrent glioblastoma or a related brain cancer will receive the stem cells. The main goal i…
Matched conditions: RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 4
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 05:08 UTC
-
Engineered immune cells target deadly brain tumors in new trial
Disease control Recruiting nowThis early-stage trial tests a new treatment for adults with high-grade gliomas that have returned or worsened. The therapy uses the patient's own immune cells, modified in a lab to recognize and attack tumor cells, and delivers them directly into the brain. The main goals are to…
Matched conditions: RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 4
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New hope for aggressive brain tumors: drug combo shows promise before surgery
Disease control Recruiting nowThis study tests two drugs, GI-102 and pembrolizumab, given before surgery to people whose aggressive brain cancer (glioblastoma) has returned. The goal is to see if these drugs can shrink the tumor and help the immune system fight the cancer. About 36 adults will take part, and …
Matched conditions: RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 4
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC